Correction to: An in vitro Assessment of Thermo-Reversible Gel Formulation Containing Sunitinib Nanoparticles for Neovascular Age-Related Macular Degeneration
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
---|---|
Enthalten in: |
AAPS PharmSciTech - 25(2024), 3 vom: 14. März |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Bhatt, Priyanka [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
BKL: |
---|
Anmerkungen: |
© The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists 2024 |
---|
doi: |
10.1208/s12249-024-02782-1 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR05515042X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR05515042X | ||
003 | DE-627 | ||
005 | 20240327064925.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240315s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1208/s12249-024-02782-1 |2 doi | |
035 | |a (DE-627)SPR05515042X | ||
035 | |a (SPR)s12249-024-02782-1-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
084 | |a PHARM |q DE-84 |2 fid | ||
084 | |a 44.40 |2 bkl | ||
100 | 1 | |a Bhatt, Priyanka |e verfasserin |4 aut | |
245 | 1 | 0 | |a Correction to: An in vitro Assessment of Thermo-Reversible Gel Formulation Containing Sunitinib Nanoparticles for Neovascular Age-Related Macular Degeneration |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists 2024 | ||
700 | 1 | |a Narvekar, Priya |4 aut | |
700 | 1 | |a Lalani, Rohan |4 aut | |
700 | 1 | |a Chougule, Mahavir Bhupal |4 aut | |
700 | 1 | |a Pathak, Yashwant |4 aut | |
700 | 1 | |a Sutariya, Vijaykumar |4 aut | |
773 | 0 | 8 | |i Enthalten in |t AAPS PharmSciTech |d Springer International Publishing, 2000 |g 25(2024), 3 vom: 14. März |w (DE-627)SPR02478785X |w (DE-600)2052070-0 |x 1530-9932 |7 nnns |
773 | 1 | 8 | |g volume:25 |g year:2024 |g number:3 |g day:14 |g month:03 |
856 | 4 | 0 | |u https://dx.doi.org/10.1208/s12249-024-02782-1 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_SPRINGER | ||
912 | |a FID-PHARM | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OPC-PHA | ||
936 | b | k | |a 44.40 |q VZ |
951 | |a AR | ||
952 | |d 25 |j 2024 |e 3 |b 14 |c 03 |